ArticleCrohn's & colitis 3602019
Elevated Pretreatment Plasma Oncostatin M Is Associated With Poor Biochemical Response to Infliximab.
Article in Crohn's & colitis 360, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed.
- Pharmacometric Targets During Anti-TNF Induction and Their Association with Deep Remission in Pediatric Crohn's Disease.Clinical pharmacokinetics · 2026Article
- Evaluation of pharmacokinetic metrics and pharmacodynamic biomarkers associated with endoscopic healing in pediatric Crohn's disease patients treated with anti-tumor necrosis factor biologics.Crohn's & colitis 360 · 2026Article
- Article
- Unravelling neutropenic enterocolitis: insights from gut microbiota, and intestinal barrier analyses.Experimental hematology & oncology · 2025Article
- Integrating early response biomarkers in pharmacokinetic models: A novel method to individualize the initial infliximab dose in patients with Crohn's disease.Clinical and translational science · 2025Article
- Infliximab Precision Dosing in Inflammatory Bowel Disease (IBD) Patients: A Review of Current Literature.Cureus · 2024Review
- Challenges in IBD Research 2024: Precision Medicine.Inflammatory bowel diseases · 2024Review
- Association between Ustekinumab Trough Levels, Serum IL-22, and Oncostatin M Levels and Clinical and Biochemical Outcomes in Patients with Crohn's Disease.Journal of clinical medicine · 2024Article
- Role of Oncostatin M in the prognosis of inflammatory bowel disease: A meta-analysis.World journal of gastrointestinal surgery · 2024Article
- Precision Dosing of Anti-TNF Therapy in Pediatric Inflammatory Bowel Disease.Current gastroenterology reports · 2023Review
- Distinct transcriptional signatures in purified circulating immune cells drive heterogeneity in disease location in IBD.BMJ open gastroenterology · 2023Article
- Personalize, participate, predict, and prevent: 4Ps in inflammatory bowel disease.Frontiers in medicine · 2023Review
- Review
- Pursuing neutrophils: systematic scoping review on blood-based biomarkers as predictors of treatment outcomes in inflammatory bowel disease.Therapeutic advances in gastroenterology · 2023Article
- The Future of Precision Medicine to Predict Outcomes and Control Tissue Remodeling in Inflammatory Bowel Disease.Gastroenterology · 2022Review
- High oncostatin M predicts lack of clinical remission for patients with inflammatory bowel disease on tumor necrosis factor α antagonists.Scientific reports · 2022Article
- Research-Based Product Innovation to Address Critical Unmet Needs of Patients with Inflammatory Bowel Diseases.Inflammatory bowel diseases · 2021Article
- Oncostatin M Is a Biomarker of Diagnosis, Worse Disease Prognosis, and Therapeutic Nonresponse in Inflammatory Bowel Disease.Inflammatory bowel diseases · 2021Article
- Achieving Target Infliximab Drug Concentrations Improves Blood and Fecal Neutrophil Biomarkers in Crohn's Disease.Inflammatory bowel diseases · 2021Article
- Tumour necrosis factor inhibitors in inflammatory bowel disease: the story continues.Therapeutic advances in gastroenterology · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundWe hypothesized that elevations of plasma Oncostatin M (OSM) would be associated with infliximab nonresponse.
methodsPlasma OSM was measured in Crohn disease patients pre-infliximab with biochemical response (>50% reduction in fecal calprotectin) as the primary outcome.
resultsThe median OSM in biochemical responders was 86 (69-148) pg/mL compared with 166 (74-1766) pg/mL in nonresponders (
conclusionsElevated preinfliximab plasma OSM and nCD64 surface expression were both associated with poor biochemical outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.